Medtech Execs On The Move, September 2013
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.
With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.